UKILD-Long COVID
Research type
Research Study
Full title
The UK Interstitial Lung Disease Long-COVID19 study (UKILD-Long COVID): understanding the burden of Interstitial Lung Disease in Long COVID
IRAS ID
297891
Contact name
M E Weeks
Contact email
Sponsor organisation
Imperial College London,
Clinicaltrials.gov Identifier
Clinicaltrials.gov Identifier
NA, NA
Duration of Study in the UK
5 years, 7 months, 22 days
Research summary
Background
A reported effect of contracting COVID-19 is developing Post COVID Interstitial Lung Disease (PC-ILD). PC-ILD is inflammation, scarring (fibrosis), or both that can cause permanent lung damage. Inflammation may be reversible but can progress to fibrosis which may worsen. The number of people with ILD is not clear but could be high. Highlighting the disease history and risk factors for development of lung fibrosis could help define better treatment options.
What
This will be a longitudinal observational study of patients with suspected ILD following COVID-19, to determine the prevalence of ILD 12-36 months following infection and factors that influence the recovery or worsening of the condition.
Who
Patients with proven COVID infection with persistent respiratory symptoms prompting further clinical care and a CT scan of the lungs.
Where
CT imaging and lung function will be performed as part of routine investigation in the post-COVID clinics and NHS research sites. Patients who consent to additional tests, will have these done by the research team at the same location.
How
Following assessment of post COVID patients at baseline (3-6 months post infection), those with clinical and radiological features suggestive of ILD will be included into the study. A CT will be offered at 12- 36 months (+/- 3 months) post infection. Those with no features of ILD will be invited to enrol as part of the control cohort. Participants will be offered lung function testing at 3 and 12-36 months and asked to complete questionnaires assessing for breathlessness, fatigue, cognition and quality of life. They will be offered the opportunity to perform a walk test to assess aerobic capacity and blood tests for genetic testing and analysis. People recruited via the research study who have satisfied the inclusion/exclusion criteria, will be asked to undergo a chest CT scan at a timepoint of 36 months post infection.REC name
London - Riverside Research Ethics Committee
REC reference
21/HRA/3313
Date of REC Opinion
10 Aug 2021
REC opinion
Favourable Opinion